Glenmark Pharma: Ashish Dhawan portfolio stock surges 9% as USFDA clears Aurangabad unit

Brokerage firm Investec expects that earnings momentum, along with strong cash flow generation, will continue to support the company’s ongoing re-rating.

Leave a Reply

Your email address will not be published. Required fields are marked *